Novel therapeutics for type 2 diabetes: insulin resistance
- 11 October 2014
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 17 (4), 319-334
- https://doi.org/10.1111/dom.12400
Abstract
Insulin resistance (IR) plays an important role in the pathogenesis of type 2 diabetes (T2D) and cardiovascular disease. Hence improving IR is a major target of treatment in patients with T2D. Obesity and lack of exercise are major causes of IR. However, recent evidence implicates sleep disorders and disorders of the circadian rhythm in the pathogenesis of IR. Weight loss and lifestyle changes are the cornerstone and most effective treatments of IR, but adherence and patient's acceptability are poor. Bariatric surgery results in significant and sustainable long‐term weight loss associated with beneficial impact on IR and glucose metabolism, making this an attractive treatment option for patients with T2D. Currently available pharmacological options targeting IR (such as metformin and thiazolidinediones) do not maintain glycaemic measures within targets long term and can be associated with significant side effects. Over the last two decades, many pharmacological agents targeting different aspects of the insulin signalling pathway were developed to improve IR, but only a minority reached clinical trials. Such treatments need to be specific and reversible as many of the components of the insulin signalling pathway are involved in other cellular functions such as apoptosis. Recent evidence highlighted the role of circadian rhythm and sleep‐related disorders in the pathogenesis of IR. In this article, we review the latest developments in the pharmacological and non‐pharmacological interventions targeting IR including bariatric surgery. We will also review the role of circadian rhythm and sleep‐related disorders in the development and treatment of IR.Funding Information
- National Institute for Health Research
This publication has 189 references indexed in Scilit:
- Grape Resveratrol Increases Serum Adiponectin and Downregulates Inflammatory Genes in Peripheral Blood Mononuclear Cells: A Triple-Blind, Placebo-Controlled, One-Year Clinical Trial in Patients with Stable Coronary Artery DiseaseCardiovascular Drugs and Therapy, 2012
- Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with DiabetesThe New England Journal of Medicine, 2012
- Mechanisms for Insulin Resistance: Common Threads and Missing LinksCell, 2012
- Apelin and insulin resistance: Another arrow for the quiver?Journal of Diabetes, 2011
- Circadian Integration of Metabolism and EnergeticsScience, 2010
- Role of Sleep and Sleep Loss in Hormonal Release and MetabolismPublished by S. Karger AG ,2009
- Adverse metabolic and cardiovascular consequences of circadian misalignmentProceedings of the National Academy of Sciences of the United States of America, 2009
- Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?BMJ, 2007
- Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetesThorax, 2007
- Mechanisms linking obesity to insulin resistance and type 2 diabetesNature, 2006